ÂÜÀòÂÒÂ×

Frank Misselwitz MD, PhD, is Actimed’s Chief Medical Officer. He joined the Company from Bayer AG, where he was Corporate Vice President and Therapeutic Area Head in clinical development. With a background in academia and industry, he has over 30 years extensive pharmaceutical industry experience. Frank supported the development of Humira ($20billion in 2018) at Knoll AG and Abbott and has completed development of multiple cardiovascular drugs (including rivaroxaban). Frank is a member of Scientific Advisory Board of the German Center for Cardiovascular Research and the Centre for Thrombosis and Haemostasis University of Mainz Germany; he has extensive clinical research experience including the landmark COMPASS trial. His previous academic research experience was gained in UK, USA, Germany and Russia and he is the author of over 250 publications, has a cumulated impact factor of 1200 and a Hirsch-Index of 67.